Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be reporting earnings this Tuesday afternoon. Here’s what you need to know.
Gilead Sciences beat analysts’ revenue expectations by 3.7% last quarter, reporting revenues of $7.77 billion, up 3% year on year. It was a strong quarter for the company, with a solid beat of analysts’ revenue estimates and a beat of analysts’ EPS estimates.
Is Gilead Sciences a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, analysts are expecting Gilead Sciences’s revenue to grow 1.9% year on year to $7.68 billion, slowing from the 7.1% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.83 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Gilead Sciences has missed Wall Street’s revenue estimates twice over the last two years.
Looking at Gilead Sciences’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Biogen’s revenues decreased 7.1% year on year, beating analysts’ expectations by 3.6%, and Amgen reported revenues up 8.6%, topping estimates by 4.1%. Amgen traded up 9% following the results.
Read our full analysis of Biogen’s results here and Amgen’s results here.
Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the therapeutics stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.1% on average over the last month. Gilead Sciences is up 24.2% during the same time and is heading into earnings with an average analyst price target of $139.46 (compared to the current share price of $152.46).
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.